Gastroesophageal cancers: Progress and problems

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 9, 2008, Pages 813-814

  Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT;

BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; EARLY DIAGNOSIS; EDITORIAL; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; GASTROESOPHAGEAL REFLUX; HUMAN; MINIMALLY INVASIVE SURGERY; MORBIDITY; OBESITY; QUALITY OF LIFE; STOMACH ADENOCARCINOMA; STOMACH SURGERY;

EID: 56049099563     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0061     Document Type: Editorial

References (15)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
3. Parkin DM, Bray F, Ferlay J, Pisani F. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
5. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
6. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
7. DeMeester SR. New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg 2008;85:S747-S750.
8. DeMeester SR. EMR for intramucosal adenocarcinoma of the esophagus: does one size fit all? Gastrointest Endosc 2007;65:14-15.
9. DeMeester SR. Endoscopic mucosal resection and vagal-sparing esophagectomy for high-grade dysplasia and adenocarcinoma of the esophagus. Semin Thorac Cardiovasc Surg 2005;17:320-325.
10. Tanaka M, Ono H, Hasuike N, Takizawa K. Endoscopic submucosal dissection of early gastric cancer. Digestion 2008;77(Suppl 1):23-28.
11. Kelsey CR, Chino JP, Willett CG, et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 2007;69:770-776.
12. Javeri H, Arora R, Correa AM, et al. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 2008; in press.
13. De Roock W, Piessevaux H, De Schutter J, et al. KPLAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-515.
14. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
15. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.